retatrutide trial news today Positive Top-line Results for in Diabetes: TRANSCEND-T2D-1 Retatrutide Results: 28.3% Weight Loss

Whats Actually Available KFDA Approval Status (2026) Koreas drug regulatory body (MFDS, formerly KFDA) has formally approved the following GLP-1 receptor agonists

FDA does not review their safety, effectiveness, or quality) (U.S

In a 10-week clinical trial, a daily dose of 20 mg oral semaglutide achieved a steady-state plasma concentration of 30 nM, and when daily dose of oral semaglutide was increased to 40 mg, the semaglutide plasma concentration reached about 60 nM (102), which was over a thousand times higher than the EC50 of semaglutide for GLP-1R activation (95)

Additional information Enhanced Digital Features To view enhanced digital features for this article go to Rights and permissions About this article Cite this article Nagahisa, T., Saisho, Y

[thelancet.com] Significant reductions in HbA1c and body weight across multiple dosing regimens